IFRX: INF904 advances in ANCA vasculitis with phase II trials planned and strong regulatory engagement
A strategic pivot prioritizes ANCA vasculitis with INF904, designed for better safety and efficacy, and vilobelimab as a bridging option amid competitor withdrawals. Regulatory engagement is active, with phase II trials set to begin early next year and broader renal indications under consideration…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.